Currently, the only molecularly guided first-line treatment for HGSC targets tumors with BRCA1/2 deficiency, or more broadly, homologous recombination deficiency (HRD), which are associated with greater sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors (4, 5). The gene discussed is BRCA1; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.